This inventor holds 1 USPTO granted patent. Top assignee: Musc Foundation for Research Development. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Anjan Motamarry: Innovator in Intravascular Drug Delivery Systems
Introduction
Anjan Motamarry is a notable inventor based in Charleston, SC (US). He has made significant contributions to the field of medical technology, particularly in drug delivery systems. His innovative approach aims to enhance patient safety and treatment efficacy.
Latest Patents
Anjan Motamarry holds a patent for "Extracorporeal drug removal for intravascular triggered drug delivery systems." This system is designed to reduce toxicity from intravascular triggered drug delivery. It includes a chamber with an inflow port, an outflow port, and a filter positioned upstream of the outflow port. The system features a trigger module that activates the release of a drug from an intravascular triggered drug delivery system present in the blood within the chamber. The method involves removing blood containing the drug delivery system from a patient's vascular system, applying a trigger to release the drug, filtering the drug from the blood, and returning the filtered blood to the patient.
Career Highlights
Anjan Motamarry is associated with the MUSC Foundation for Research Development, where he continues to work on advancing medical technologies. His dedication to research and innovation has positioned him as a key figure in his field.
Collaborations
Anjan collaborates with Dieter Haemmerich, a fellow innovator in the medical research community. Their partnership focuses on developing cutting-edge solutions for drug delivery and patient care.
Conclusion
Anjan Motamarry's work in intravascular drug delivery systems exemplifies the impact of innovation in healthcare. His patent and ongoing research contribute to improving patient outcomes and reducing treatment-related risks.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
